Posts Tagged ‘Disclaimer’

Lorcaserin and Qnexa

Lorcaserin and Qnexa, two new weight loss drugs that bear recommendations from the FDA advisory panel aspire to gain FDA approval in 2012.

Obesity-related illnesses may become quite serious and even fatal. Remaining overweight puts stress on your body and increases the possibility of serious health risks, including diabetes, heart disease, high blood pressure and cholesterol. Current obesity solutions are limited. While diet and exercise may be the number one recommendation for weight loss, it’s not effective for everyone. The only other proven weight reduction choice is bariatric surgery, the industry health risk in and when itself.

The makers of two new weight reduction drugs, Lorcaserin and Qnexa, hope to bring new choices to the marketplace for those struggling to shed weight. Both drugs have shown remarkable weight loss leads to initial studies. Both drugs are also denied FDA approval to begin with and are awaiting news on their second attempt.


The FDA denied Lorcaserin the very first time due to the health concern surrounding tumor development and heart health negative effects. Now you ask , weather the advantages outweigh the potential risks of the drug. Lorcaserin changes brain chemistry to help you feel full. It helps to manage mood and appetite, things many dieters complain about.


Though Qnexa increased heart rate during clinical trials, it did reduce blood pressure, cholesterol, C-reactive protein and the risk of diabetes. It also showed a remarkable 10% weight reduction over the course of a year. Essentially, it’s a low dose of both phentermine and topiramate. The controversy isn't over the effectiveness of this new weight reduction drug. Qnexa works to reduce obesity. Its only a matter of weighing the possibility risks associated with this drug combination.

More about this topic

    FDA Panel Vote Against Accessibility to New Weight Loss Pill QnexaPrescription Diet Pill Sibutramine Withdrawn at US FDA RequestFDA-approved Weight reduction Drug – Panel Suggests Meridia Withdrawal

    According to the FDA guidelines for weight loss drugs, trials must test people with a BMI greater than 30 with comorbidities, such as cardiovascular disease, anti snoring, hypertention and kind 2 diabetes. Furthermore, after one year, participants of the trial should have an appetite suppressant of 5% or even more, along with improved cholesterol, blood pressure level and glycerine.

    If Lorcaserin and Qnexa obtain FDA approval, they’ll be the first one to generate the label in over 13 years. Both weight loss drugs are currently awaiting a final decision.


    Hellmich, Nancy. "Diet Drug Qnexa Awaits OK Amid Safety Concerns,” USA Today. May 2012.

    Rubin, Rita. WebMD. “FDA Panel Votes in support of Weight Loss Pill Qnexa,” Feb 2012.

    “FDA Breifing Document: NDA 22529-Lorcaserin Hydrochloride Tablets,” Endocrinology and Metabolic Drugs Advisory Committee Meeting. May 2012.

    “Guidance for Industry: Developing Products for Weight loss,” US Department of Health insurance and Human Services, Food and Drug Administration. Feb 2007.

    “FDA Panel Gives Blessing to New Weight-Loss Drug,” HealthDay. May 2012.

    Disclaimer: The information found in this article is for educational purposes only and cannot be used for diagnosis in order to guide treatment with no opinion of a health professional. Any reader who is concerned about their health should contact a doctor for advice.